Ertapenem: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) |
||
| Line 22: | Line 22: | ||
'''| [[Ertapenem clinical studies|Clinical Studies]]''' | '''| [[Ertapenem clinical studies|Clinical Studies]]''' | ||
'''| [[Ertapenem dosage and administration|Dosage and Administration]]''' | '''| [[Ertapenem dosage and administration|Dosage and Administration]]''' | ||
'''| [[Ertapenem how supplied|How Supplied]]''' | '''| [[Ertapenem how supplied|How Supplied]]''' | ||
'''| [[Ertapenem labels and packages|Labels and Packages]]''' | '''| [[Ertapenem labels and packages|Labels and Packages]]''' | ||
== Mechanism of action == | == Mechanism of action == | ||
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to [[penicillin binding proteins]] (PBPs). In [[Escherichia coli]], it has strong affinity toward [[Penicillin binding proteins|PBPs]] 1a, 1b, 2, 3, 4 and 5 with preference for [[Penicillin binding proteins|PBPs]] 2 and 3. | Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to [[penicillin binding proteins]] (PBPs). In [[Escherichia coli]], it has strong affinity toward [[Penicillin binding proteins|PBPs]] 1a, 1b, 2, 3, 4 and 5 with preference for [[Penicillin binding proteins|PBPs]] 2 and 3. | ||
Revision as of 13:35, 24 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz®. It is structurally very similar to meropenemin that it possess a 1-β-methyl group.
Category
Carbapenems
US Brand Names
INVANZ®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of action
Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3.